Marshall Wace’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Marshall Wace’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5	Closed	–	–	1975
2019 Q1	$0	Buy	+5	New	+$167	﹤0.01%	2137
2015 Q1	–	Sell	-7,935	Closed	-$1.83M	–	968
2014 Q4	$1.83M	Buy	+7,935	New	+$1.7M	0.02%	474

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace's BLCM Position: Q2 2019 in Review

Marshall Wace sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 5 shares.

Marshall Wace first reported a position in BLCM in Q4 2014 and held it in 2 quarters. The position peaked at $1.83M in Q4 2014. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Marshall Wace reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Marshall Wace sold 5 Bellicum Pharmaceuticals, Inc. shares in Q2 2019.
Marshall Wace first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
Marshall Wace's Bellicum Pharmaceuticals, Inc. position peaked at $1.83M in Q4 2014.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Marshall Wace's 13F filing for Q2 2019, filed 14 Aug 2019.